Exelixis, Inc. (EXEL) Competitors & Peers
The 5 largest companies in the same industry as Exelixis, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $506.10 | P/E 29.8RSI 43Cap 130.0 B |
| REGN | Peer | $783.89 | P/E 19.4RSI 48Cap 80.8 B |
| ARGX | Peer | $995.23 | P/E 38.0RSI 53Cap 62.1 B |
| RVMD | Peer | $189.46 | RSI 42Cap 42.5 B |
| CSLLY | Peer | $30.94 | P/E 18.2RSI 71Cap 60.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- CAGSupplier
Own 10-Q customer-concentration disclosure: AffiliatesOfCencoraInc = 22% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - UNHSupplier
Own 10-Q customer-concentration disclosure: AffiliatesofOptumSpecialtyPharmacy = 9% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CVSSupplier
Own 10-Q customer-concentration disclosure: AffiliatesofCVSHealthCorporation = 16% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
Own 10-Q customer-concentration disclosure: AffiliatesofMcKessonCorporation = 18% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - TKPHFSupplier
Own 10-Q customer-concentration disclosure: Takeda = 7% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗